Pfizer's Oral Weight Loss Drug Shows Promise in Clinical Trials.
Pfizer's GLP-1 agonist has shown potential for weight loss in people with type 2 diabetes, according to new Phase II data published in the JAMA network. The drug is part of a growing field of obesity drugs, many of which started as diabetes medications, and are expected to become the biggest drug class in history with more than $100 billion on the line.